Description
Ivosidenib, sold under the brand name Tibsovo, is used in adults whose cancer is newly diagnosed and who are either 75 years and older or cannot be treated with other anticancer drugs. Ivosidenib blocks the protein made by the mutated IDH1 gene. Blocking this protein may help keep cancer cells from growing. Ivosidenib is a type of enzyme inhibitor and a type of targeted therapy for patients diagnosed with Glioma, Acute Myeloid Leukemia (AML), Cholangiocarcinoma, and Chondrosarcoma.